Objective(s): To assess the levels of systemic inflammatory markers of age-associated comorbidities in people living with HIV (PLHIV) on long term suppressive antiretroviral therapy (ART).
Introduction
The most remarkable achievement in the battle against the Human Immunodeficiency Virus (HIV) is the discovery of very efficient, well-tolerated combinational antiretroviral therapy (ART) , that has transformed the deadly viral infection into a chronic, manageable disease. In the absence of a cure, HIV-infection requires lifelong treatment. Though treatment successfully controls HIV-replication and prevents opportunistic infections, HIV-infected persons on long term ART not only succumb to death at an earlier age than the HIVuninfected counterparts but also suffer from some maladies that are typically associated with human aging [1] . The effcet of HIV-associated inflammation and immune activation on premature onset of immunosenescence despite effective viral suppresion are thought to be the primary reasons for early aging in people living with HIV (PLHIV) [2] .
Chronic, low-grade systemic inflammation resulting from an increased pro-inflammatory state contributes to the progressive pathophysiological changes associated with aging. This process of increase in pro-inflammation followed by a chronic inflammatory state is termed as "inflamm-aging" and is a significant risk factor for morbidity and mortality in the elderly people [3] . The inflammatory environment triggers the development of several age-related noninfectious comorbidities (NICMs) [1] . In HIV infection, it is believed that viral persistence in a rare population of long-lived, latently infected cells despite successful ART contributes to the chronic inflammatory state [1] .
Unlike in high-income countries (HIC), the ART program in low-and middle-income countries (LMIC) like India, follows a public health approach with a standardized regimen for all PLHIV. As of December 2016, nearly one million PLHIV were receiving free ART through the government program in the country [4] . The recommended first-line ART regimen includes one non-nucleoside reverse transcriptase inhibitor (NNRTI), either nevirapine (NVP) or efavirenz (EFV), in the backbone of two nucleoside reverse transcriptase 5 inhibitors (NRTI), either zidovudine (AZT) or tenofovir (TDF), and lamivudine (3TC) [5] .
Although perfect adherence to treatment remains a challenge, the reasonably good response to first-line therapy indicates the overall success of the ART program in the country [6] . Thus, with the expansion of the ART program and its consequences in PLHIV, the burden of agerelated non-AIDS diseases are likely to increase. Since the environment has an enormous impact on age and age-related diseases, and the genetic determinants of aging may vary across populations, studies conducted in HICs might not apply to the LMICs [7] .
The present study attempted to evaluate HIV-associated inflammation and immune activation and the contribution to Inflamm-aging in PLHIV on long-term combination ART (cART) by assessing markers of inflammation as well as aging, including a panel of 92 inflammatory markers, two well-characterized immune activation markers (sCD14 and sCD163), and telomere length. The study provides useful insights into the role of inflammation and aging in HIV-1 infected individuals despite successful ART.
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Methods
Study design and participants
The study included three groups of individuals: i) treatment-naïve PLHIV with viremia and moderate CD4 count (Pre-ART herein) ii) PLHIV of aged between 35-60 years on ART for more than five years with suppressed viremia on national first-line ART and >90% adherence to treatment (ART herein), and iii) life-style, age and gender-matched (with ART group) HIV-1 negative healthy individuals free of any kind of chronic illness (HIVNC herein). The HIV-1 positive cohort was recruited from a tertiary care ART Centre at the Government Hospital for Thoracic Medicine (GHTM), Chennai, India, at the time of routine standard-ofcare hospital visit. Exclusion criteria were pregnancy in women, Immune Reconstitution Inflammatory Syndrome (IRIS), presence of co-infections like active tuberculosis or hepatitis virus infection, history of co-morbidities like diabetes mellitus, obesity, evidence of cardiovascular disease or any chronic illness, illicit drug usage, alcohol consumption, and intake of anti-inflammatory drugs in the past one month. For the ART group, we screened 258 individuals, and recruited 55 persons who matched the above criteria for the study. After screening 166 individuals for the pre-ART group, 41 who met the eligibility criteria were recruited for the study. Plasma viral load was measured using the Abbott RealTime HIV-1 viral load assay (Abbott, US). Two individuals in the ART group had viral load >150 copies/mL (4000 and 1800 copies/mL, respectively) and had to be excluded from the study.
We screened 295 healthy individuals in and around Chennai, India, and identified 43 lifestyle, age and gender-matched individuals for the HIVNC group.
The overall study design is presented in Figure 1 . After first-time counseling and obtaining informed consent to participate in the study, 15 mL of venous blood was collected from each study participant.
Proteomic profiling of the soluble factors in plasma
Plasma samples from the Pre-ART, ART and HIVNC groups were subjected to soluble proteome analysis using the Olink ® Inflammation Panel that includes 92 inflammation-related soluble factors (Olink Bioscience AB, Uppsala, Sweden) [8] . We measured 92 markers of inflammation in the plasma samples of the three study groups. Of the 92 proteins, only 75
were detectable in >50% of the samples, and therefore our analysis was restricted to these proteins alone. Two Pre-ART samples and one HIVNC sample did not pass the quality control and had to be excluded from our analysis. We also measured two widely reported biomarkers of immune activation, sCD14 (Human CD14 Quantikine ELISA Kit R&D Systems, UK) and sCD163 (Thermo Scientific™ Pierce™ Human CD163 Kit, Thermo
Scientific, USA) in plasma.
Telomere length in peripheral blood mononuclear cells (PBMC)
As a molecular biomarker of "biological aging", the leucocyte telomere length was measured in PLHIV on ART and HIV-negative controls. Genomic DNA was extracted from PBMC using the QIAamp DNA Mini Kit (Qiagen, Germany). and telomere length was measured using the Absolute Human Telomere Length Quantification qPCRAssay Kit (AHTLQ;
ScienCell Research Laboratories, US) following manufacturer's instructions. All samples were tested in triplicate.
Total HIV-1 DNA quantification using IC-qPCR marker for HIV-1 reservoir level
To quantify total HIV-1 DNA from PBMC, internally controlled qPCR (IC-qPCR) was performed as described previously [9] . IC-qPCR was performed in duplicate using 500ng template DNA and Takara Premix Ex Taq TM (Probe qPCR) (Takara, Japan). 
Statistical analysis and data visualization
Mann Whitney U test, Chi-square test, and one-way analysis of variance (ANOVA) were performed to investigate difference in mean levels of protein expression (NPx) in the different groups under study. Multivariate linear regression for the outcome of telomere length was used to investigate the association between HIV status and HIV treatment duration adjusting for chronological age as well as other disease and patient characteristics. These same models were used to investigate evidence of mediation of the HIV-telomere relationship by soluble biomarkers. A heatmap was generated to visualize the clustering of samples based on protein expression using gplots v3.0.1 in R. Similarity in protein expression within the groups was visualized using a multi-dimensional scaling plot (MDS) in R package, edge R. All other analysis was performed using base R. P-values are not corrected for multiple comparisons, although false discovery rate was used in some of the biomarker discovery analyses.
Ethical Clearances
The study was approved by the Institutional Ethics Committee of the National Institute for 
Results
Patient characteristics
Cohort characteristics are presented in Table 1 . All three cohorts were gender matched. There were 51%, 43% and 51% of females in the Pre-ART, ART and HIVNC respectively. The median age of ART, Pre-ART and HIVNC groups were 45, 40 and 46 years respectively. In the ART group, the median (IQR) duration of treatment was 8 years (6-10 years). As per the inclusion criteria, all the patients had >90% of self-reported adherence which was further confirmed by viral load <150 copies/mL and very low-level HIV-1 reservoir with median were significantly lower in the ART group as compared to the Pre-ART group (30014 pg/mL vs. 68192 pg/mL, p<0.001, Mann Whitney U Test), but were significantly higher as compared to the HIVNC group (p=0.04, Mann Whitney U Test). We did not find any significant correlation between duration of cART and sCD14 (Spearman r: 0.163; p=0.2432) or sCD163 (Spearman r: 0.154; p=0.2720) levels in the ART group.
Soluble markers of inflammation in plasma
To identify candidate biomarkers for future study, we looked for biomarkers that differed significantly between the groups by Random Forest (RF) analysis (Figure 3a) . The proteins with the most significant differences were TNFRSF9, sCD6, sCD5, TRANCE, and CXCL9.
Hierarchical clustering analysis (HCA) with false discovery rate (FDR) <0.001, revealed
clustering of 79% (31/39) of the Pre-ART samples along with two samples from the HIVNC and one from ART groups (Figure 3b) . Seven Pre-ART samples clustered with the HIVNC and ART groups. The HCA result was consistent with that of the MDS plot ( Supplementary   Fig 1) and principal component analysis. between all the three groups (CD8A, TRANCE, sCD5, SLAMF1, and CCL23) (Figure 3c ).
Of the proteins that showed significant difference between the ART and HIVNC groups, levels of soluble NT3, CD5, TRAIL, and TRANCE were lower, but levels of ADA, MMP1, CST5 and 4E-BP1 were higher, when compared to both HIVNC and Pre-ART groups. On the other hand, CD8A, SLAMF1 and CCL23 were higher in the ART group as compared to the HIVNC group (Figure 3d ).
Telomere Length
Telomere length was analyzed only in two groups (HIVNC and ART) as PBMC were not available for the Pre-ART group. Linear regression analysis, after adjusting for chronological age and gender showed a significant negative association of HIV-1 positive status on telomere length (-2.84, 95%CI -4.012, -1.67, p<0.0001) with the ART group having significantly shorter telomeres. However, no significant association was observed between duration of treatment and telomere length after adjusting for age and markers of disease progression within the ART group. Several of the biomarkers considered were significantly associated with telomere length after adjustment for age, HIV status, and gender, these include CXCL1
and CD40 which are both weakly positively association with telomere length, MMP-10 and CX3CL1, which are positively associated with telomere length and OSM which is negatively associated; results are outlined in detail in supplementary 
Discussion
This study examined a cohort of PLHIV on long-term successful cART from India, and found that despite a median duration of eight years of suppressive cART, several soluble inflammatory markers that were found to be evaluated in HIV-1 infected untreated subjects, were also significantly elevated in the ART group as compared to the HIVNC group. This study found higher levels of the inflammatory protein CST5, a first in PLHIV, as compared to HIVNC, in addition to higher levels of 4E-BP1, SLAMF1, CCL23 and lower levels of NT3
proteins, a first in PLHIV on long term cART.
It has been reported that certain age-related NICMs like diabetes mellitus, cardiovascular disease, cancer, bone fracture and renal failure, are more common among HIV-1 infected individuals as compared to the general population. Exposure to prolonged cART along with low grade inflammation and persistent immune activation seen in HIV-infection is thought to be the cause for the increased risk of NICMs [2, 10] . Chronic inflammatory conditions and persistent immune activation are believed to be the major drivers of aging physiology.
Inflammatory biomarkers of aging and their association with co-morbid diseases has been studied well in many elderly populations. Proteins like 4E-BP1 and association of mTOR with aging and age-related diseases [11, 12] , has already been documented. However, there are no studies that have examined the response of plasma 4E-BP1 to ART. We found higher levels of 4E-BP1 in the ART group as compared to both HIVNC and the Pre-ART group, suggesting this marker may be associated with duration of HIV infection and/or exposure to antiretroviral drugs.
In the case of well-studied immune activation markers, the ART group had significantly higher levels of sCD14 like that seen in the Pre-ART group. Contradictory results that have been reported from different studies on the effect of cART on sCD14 [13] [14] [15] due to a variety of contributors [16, 17] . On the other hand, sCD163, a marker of vascular inflammation [18] and neurocognitive impairment [19] , was higher in PLHIV than in healthy controls, which is in contrast to previous reports [20] . The novelty of our study was to explore of a large panel of inflammatory markers and show significantly higher levels of MMP1 [21] , ADA [22] , CD8A [23] , SLAMF1 [24] and CCL23 [25] in PLHIV on long term ART. Many of these markers have been reported to be linked with early stages of various age-related diseases.
sCD5 and TRAIL have been reported as biomarkers of inflammation and related diseases in both HIV-infected as well as uninfected individuals [26] [27] [28] . We found lower levels of sCD5
and TRAIL in the ART group as compared to the HIVNC group. Of particular mention is the 13 association between lower plasma and cerebrospinal fluid levels of TRAIL and early
Alzheimer Disease (AD) [29] . CD5, a negative regulator of antigen receptor signal transduction in lymphocytes [30] , is reported to stimulate the production of the antiinflammatory cytokine IL-10 by B-cells [31] . Low levels of sCD5 in HIV-infected individuals, associated with the existing pro-inflammatory state could promote the development of age-related cancers and other diseases in these individuals. An earlier study conducted in a Swedish cohort reported normalization of sCD5 to a healthy state upon anti-HIV treatment [32] , which is in contrast to our findings. However, the Swedish cohort was on two decades long successful therapy and were initiated on ART in the early stages of HIVinfection, unlike our cohort which was started on ART only in stage 2 or 3 of the disease as per national guidelines and policies available then.
TRANCE/RANKL, an important regulator of bone metabolism, was found to be lower in the ART group than in HIVNC. There is existing literature to show that HIV-infected individuals treated with NRTIs and NNRTIs have lower than normal levels of circulating RANKL [33] .
Lower levels of TRANCE have been reported as an independent predictor of non-traumatic fracture indicating its effect on osteoclastogenesis [34] . Though Cystatin D (CST5) has not been well studied in HIV, our study showed altered levels of this protein in HIV-1 infected individuals. To the best of our knowledge this is the first study reporting elevated levels of CST5 in HIV infection.
NT3, another inflammatory marker, is reported to be strongly associated with neurocognitive impairment in PLHIV [35, 36] and MMP1 with senescence associated conditions [37, 38] .
Higher levels of these two proteins could be due to a favoring age-associated changes and premature aging in HIV-infected individuals with prolonged exposure to cART. The decreased expression of NT3 was also observed in colorectal cancer [39] , while increased levels of plasma MMP1 have been associated with coronary atherosclerosis [40] and cancers 14 [41, 42] further provide evidence to support the role of these proteins in disease development during aging.
Higher levels of CCL23 and SLAMF1, which are involved in monocyte activation, in the ART group could contribute to sustained release of sCD14 [43] . Further, continued immune activation could be due to several other mechanisms including, sustained HIV-replication in reservoir sites like lymph nodes and gastrointestinal tract [44] , low levels of HIV and its proteins [45, 46] , altered gut microbiota in PLHIV [47] and different ART regimens [48] .
Telomere length (TL) is a marker of replicative senescence and is a well-known predictor of health outcome in aging populations. Chronic inflammation can potentially contribute to agerelated diseases through increased production of reactive oxygen species that damage telomeres and lead to cellular and immunological senescence [49] . Several studies have noticed an association between TL and age-related diseases [50] . In HIV infection, immune activation and expanded proliferation of leukocyte subsets immediately after infection, along with uncontrolled viremia have been associated with a rapid decrease in TL [51] , followed by increase in TL with ART initiation. However, telomere induced replicative senscence with long term ART has also been reported [52] . Our study also found shorter telomeres in PLHIV on ART for >5 years and noticed a significant association between TL and inflammatory markers like CXCL1, TGF-α and IL10RA. Telomere length shortening has been well reported in several inflammatory conditions and related diseases like cancer. Zadka et al (2018) showed a positive correlation between IL10RA expression and disease pathogenesis in colorectal cancer [53] .
Our study has some limitations that merit comment. First, the HIV-infected population selected for this study were from the best pool of successfully treated individuals (free of coinfections and co-morbidities), through the Indian National ART program. The findings may not generalize to the general population of treated HIV-1 positive individuals. Second, due to the lack of earlier studies in this setting, the design of our study, and limited sample size, the conclusions drawn are limited to associations with modest significance. Also, many the statistical tests were run, but only the most significant results have been highlighted, for this reason, the results should be considered hypothesis generating. Third, the patients were not monitored virologically as a standard of care, and we only have virological data at the time of sampling. Any potential viral blips which are most unlikely reflected by the patients CD4
history could have introduced bias in the expression of inflammatory markers. However, among the few studies involving inflammatory markers in virally suppressed populations from LMICs [54, 55] , our study is the first comprehensive study on inflammation and aging, that compared a large panel of inflammatory markers in PLHIV on long term suppressive ART from India, which uses a standardized public health approach for treatment monitoring.
Finally, the telomere length comparison between the ART group and the HIVNC could not be adjusted for health factors or disease progression markers, such as CD4 as these were not measured on HIVNC. As Telomere length was taken as the average for PBMCs, the different in CD4 and CD8 cells percentages may have contributed to the magnitude of the difference; further studies investigating difference based on cell type are needed.
In conclusion, we observed several soluble inflammatory biomarkers that differed significantly between PLHIV and healthy individuals, despite eight years of successful therapy-Interestingly, several of these biomarkers have been previously shown to be associated with inflammatory conditions like cancer, cardiovascular, neurological and skeletal diseases. Put together, these data suggest that HIV-1 infected individuals, even those on long term successful ART, may be at higher risk of developing inflammatory diseases leading to inflamm-aging, a low-grade chronic inflammation which is a major risk factor for the development of many age-associated diseases and to some extent morbidity and mortality in elderly people in the general population. In addition, we found a large difference in telomere length between subjects on long-term ART and HIVNC subjects, even after adjusting of age;
this warrants further investigation.
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